• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

    7/24/23 3:59:05 PM ET
    $ICAD
    Medical/Dental Instruments
    Health Care
    Get the next $ICAD alert in real time by email
    SC 13G/A 1 fp0084605-1_sc13ga.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (AMENDMENT NO. 3)*

     

    ICAD INC.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    44934S206

    (CUSIP Number)

     

    June 30, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x]Rule 13d-1(b)
    [ ]Rule 13d-1(c)
    [ ]Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP NO. 44934S206

    13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS S.S. OR
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

     

    Granahan Investment Management LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) [ ]

    (b) [ ]

    3

    SEC USE ONLY

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Massachusetts

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5

    SOLE VOTING POWER

     

    1,354,943

     
    6

    SHARED VOTING POWER

     

    None

     
    7

    SOLE DISPOSITIVE POWER

     

    1,510,981

     
    8

    SHARED DISPOSITIVE POWER

     

    None

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,510,981

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES

     

    [ ]

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.94%

     
    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

     

    CUSIP NO. 44934S206 13G Page 3 of 5 Pages

     

    Item 1.(a)Name of Issuer:

     

    ICAD INC

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    98 Spit Brook Road, Suite 100

    Nashua, New Hampshire 03062

     

    Item 2.(a)Name of Person Filing:

     

    Granahan Investment Management LLC

     

    (b)Address of Principal Business Office or, if None, Residence:

     

    404 Wyman Street, Suite 460

    Waltham, MA 02451

     

    (c)Citizenship:

     

    State of Massachusetts

     

    (d)Title of Class of Securities:

     

    Common Stock, $0.01 par value

     

    (e)CUSIP Number:

     

    44934S206

     

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    (a)[ ]Broker or dealer registered under Section 15 of the Exchange Act.
    (b)[ ]Bank as defined in Section 3(a)(6) of the Exchange Act.
    (c)[ ]Insurance company as defined in Section 3(a)(19) of the Exchange Act.
    (d)[ ]Investment company registered under Section 8 of the Investment Company Act.
    (e[ x]An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)[ ]An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)[ ]A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)[ ]A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
    (i)[ ]A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

     

     

    CUSIP NO. 44934S206 13G Page 4 of 5 Pages

     

    Item 4.Ownership.

     

    (a) Amount beneficially owned: 1,510,981
    (b) Percent of class: 5.94%
    (c) Number of shares as to which the person has:  
      (i) Sole power to vote or to direct the vote: 1,354,943
      (ii) Shared power to vote or to direct the vote: 0
      (iii) Sole power to dispose or to direct the disposition of: 1,510,981
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. [ ]

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    All of the Shares set forth in Item 4 are owned by various investment advisory clients of Granahan Investment Management LLC, which is deemed to be a beneficial owner of those shares pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, due to its discretionary power to make investment decisions over such shares and/or its ability to vote such shares.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable

     

     

     

    CUSIP NO. 44934S206 13G Page 5 of 5 Pages

     

    Item 10.Certification.

     

    By signing below the undersigned certifies that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Granahan Investment Management LLC  
           
      By: /s/Brian Granahan  
      Name: Brian Granahan  
      Title: Chief Compliance Officer  
           
      Date: July 24, 2023  

     

     

     

     

    Get the next $ICAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICAD

    DatePrice TargetRatingAnalyst
    4/17/2025Buy → Neutral
    BTIG Research
    4/17/2025Buy → Hold
    Laidlaw
    1/18/2022Buy → Neutral
    Guggenheim
    1/5/2022$22.00 → $16.00Outperform
    Oppenheimer
    11/10/2021$22.00 → $18.00Market Outperform
    JMP Securities
    More analyst ratings

    $ICAD
    Financials

    Live finance-specific insights

    See more
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer

      The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet's wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD's seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet's growth and leadership in cancer screening and artificial intelligenceFollowing the completion of the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio of solutionsRadNet will host a conference call and

      4/15/25 4:01:37 PM ET
      $ICAD
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Specialities
    • iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024

      NASHUA, N.H., March 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full year ended December 31, 2024.  Fourth Quarter 2024 Highlights (Year-over-Year Performance): Total ARR (Annual Recurring Revenue) was $9.8 million, up 11% year over yearTotal revenues increased 14% to $5.4 millionGross Profit Margin of 86%382 Total deals closed in 2024, 42 of which were ProFound CloudProFound Detection V4.0 granted FDA clearanceExpanded global reach with ne

      3/19/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iCAD Reports Financial Results for First Quarter Ended March 31, 2025

      NASHUA, N.H., May 13, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2025.  First Quarter 2025 Highlights (Year over Year Performance): Total ARR (Annual Recurring Revenue) was $10.7 million, up 18% year over yearQ1 total revenues of $4.9 millionGross Profit Margin of 86%92 Total deals closed in Q1, 19 of which were ProFound Cloud Dana Brown, President and CEO of iCAD commented, "We saw meaningful progress this quarter with increasing a

      5/13/25 4:01:00 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Clinical AI Platforms Expand Globally Amid Regulatory and Market Tailwinds

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Across the western healthcare landscape, artificial intelligence (AI) is being increasingly adopted to simplify authorizations and cut through layers of bureaucratic inefficiency. Rather than replacing physicians — a scenario some tech leaders like Bill Gates have speculated about — the goal is to enhance the capabilities of healthcare professionals. Momentum in this space is being driven by recent initiatives from companies like Avant Technologies, Inc. (OTCQB:AVAI), Koninklijke Philips N.V. (NYSE:PHG), HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF), RadNet, Inc. (NASDAQ:RDNT)

      4/29/25 11:10:00 AM ET
      $ICAD
      $PHG
      $RDNT
      Medical/Dental Instruments
      Health Care
      Medical Electronics
      Medical Specialities
    • iCAD Collaborates with Microsoft to provide access to its Mammography Solutions in Microsoft's Precision Imaging Network (PIN)

      NASHUA, N.H., April 29, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company"), a global leader in clinically proven AI-powered cancer detection solutions, announced today a collaboration with Microsoft, to include a set of AI-powered mammography solutions in iCAD's ProFound Breast Health Suite on Microsoft's Precision Imaging Network. The iCAD and Microsoft collaboration provides access to automated radiology mammography reporting for patients through Microsoft's advanced radiology reporting platform, PowerScribe. iCAD's ProFound AI® Breast Health Suite will be fully cloud-hosted across Microsoft's extensive network, providing radiologists and healthcare providers wit

      4/29/25 8:00:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    SEC Filings

    See more
    • SEC Form 10-Q filed by iCAD Inc.

      10-Q - ICAD INC (0000749660) (Filer)

      5/13/25 4:33:34 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form 425 filed by iCAD Inc.

      425 - ICAD INC (0000749660) (Subject)

      5/13/25 4:11:42 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ICAD INC (0000749660) (Filer)

      5/13/25 4:11:17 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • iCAD downgraded by BTIG Research

      BTIG Research downgraded iCAD from Buy to Neutral

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD downgraded by Laidlaw

      Laidlaw downgraded iCAD from Buy to Hold

      4/17/25 8:29:51 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • icad downgraded by Guggenheim

      Guggenheim downgraded icad from Buy to Neutral

      1/18/22 7:19:48 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Brown Dana R gave a grant of 11,483 shares, decreasing direct ownership by 17% to 54,350 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      4/16/25 9:50:42 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Officer Lonnqvist Eric gave a grant of 7,345 shares, decreasing direct ownership by 46% to 8,488 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      4/16/25 9:50:12 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • Officer Brown Dana R was granted 25,833 shares, increasing direct ownership by 65% to 65,833 units (SEC Form 4)

      4 - ICAD INC (0000749660) (Issuer)

      2/27/25 9:55:47 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

      SC 13G/A - ICAD INC (0000749660) (Subject)

      2/14/24 9:00:29 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iCAD Inc. (Amendment)

      SC 13G/A - ICAD INC (0000749660) (Subject)

      7/24/23 3:59:05 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by iCAD Inc.

      SC 13G - ICAD INC (0000749660) (Subject)

      3/15/23 3:15:23 PM ET
      $ICAD
      Medical/Dental Instruments
      Health Care

    $ICAD
    Leadership Updates

    Live Leadership Updates

    See more
    • iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

      NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnersh

      4/8/25 10:19:01 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

      NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD) a global leader in providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Dr. Hricak to its Board of Directors, effective immediately. Dr. Hricak is a renowned radiologist and researcher with over 40 years of experience in the field. For more than 20 years, she was Chair of the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSK) in New York City, a position from which she stepped down in January 2023. She continues to serve on the faculty of MSK; she holds the C

      2/27/24 9:05:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care
    • iCAD Expands Board of Directors with Appointment of Michael J. Doyle, FACHE as New Board Member

      NASHUA, N.H., Jan. 30, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, announced today the appointment of Michael J. Doyle to its Board of Directors, effective immediately. Mr. Doyle is a seasoned technology and healthcare executive with over 35 years of experience. He is currently the CEO of Spire Health, a leading healthcare technology company focused on improving health outcomes for cardiorespiratory patients through continuous virtual patient monitoring. Spire along with Mr. Doyle's recent companies all achieved measu

      1/30/24 8:00:00 AM ET
      $ICAD
      Medical/Dental Instruments
      Health Care